Mosanna Therapeutics Launches With $80 Million To Advance Novel Nighttime Nasal Spray For Obstructive Sleep Apnea
June 9 (Reuters) -
MOSANNA THERAPEUTICS LAUNCHES WITH $80 MILLION TO ADVANCE NOVEL NIGHTTIME NASAL SPRAY FOR OBSTRUCTIVE SLEEP APNEA
MOSANNA THERAPEUTICS: FINANCING LED BY PIVOTAL BIOVENTURE PARTNERS AND EQT LIFE SCIENCES
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.